NetraMark Holdings (TSE:AIAI) has released an update.
NetraMark Holdings Inc. has partnered with the National Institute of Mental Health to boost psychiatric research using their NetraAI platform, which will analyze ketamine clinical trials for psychiatric disorders. The AI-driven analysis aims to enhance precision medicine by identifying key variables that influence treatment outcomes, potentially revolutionizing future clinical trials. This collaboration marks a significant step in integrating AI technology to improve understanding and treatment of complex mental health conditions.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
